Actelion Chooses GENEART as Exclusive Supplier for DNA Engineering & Processing Services
Framework agreement with Actelion Pharmaceuticals Ltd. signed
"Gene optimization and gene synthesis offer many advantages over conventional methods in molecular biology. For instance, genes can be tailored to the respective customer project by our GeneOptimizer® software without any restrictions and subsequently produced within a few days. This not only shortens development times for biopharmaceuticals, but also increases the yield and thus reduces production and project costs. The fully DIN EN ISO 9001:2000 certified processes of GENEART and the world-wide highest production capacities additionally ensure reliable and quick processing of customer projects with observance of the required quality standards for the development of pharmaceutical agents", Prof. Dr. Ralf Wagner, CEO of GENEART AG, explains.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.